tradingkey.logo

BUZZ-Natera falls as $96 mln patent verdict overturned

ReutersFeb 25, 2025 12:20 PM

Shares of genetic testing firm Natera NTRA.O fall 2.3% to $154.80 premarket, as a $96 mln jury verdict against rival CareDx CDNA.O gets overturned

U.S. District Judge Colm Connolly rules that the patents Natera accused CareDx of infringing were invalid, dismissing Natera's 2024 trial win over patent rights in DNA testing technology for kidney transplants

Natera plans to appeal the decision and pursue "all available remedies"

CareDx's attorney said the decision was "the right outcome on the law and for organ transplant patients"

A jury had previously said that CareDx infringed one of the patents and awarded Natera $96.3 million in damages, but the judge's decision overturned this verdict

NTRA more than doubled in 2024

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI